ClinicalTrials.gg

Program

CAR-T

Its studies are mostly in Connective Tissue Diseases · Colorectal Neoplasms, led by Guangzhou Bio-gene Technology.

Furthest: no phase, since Aug 26, 20253 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Guangzhou Bio-gene Technology30 open or runningno phasesince Aug 26, 2025Aug 26, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 26, 2025First studies: 3 no phase studiesFirst studyNCT07152236, NCT07152223, NCT07152210

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07152236Solid Tumors · China–WithdrawnMar 2, 20260
NCT07152223Connective Tissue Diseases · China–WithdrawnMar 2, 20260
NCT07152210Colorectal Neoplasms · China–WithdrawnMar 2, 20260

How it is read

Names in the registry

  • “CAR-T”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.